A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.


Updates from The Motley Fool

Latest updates on Celgene from Fool.com.


Stock Performance

CELG vs. S&P 500 | 2 Year Performance
View Interactive CELG Charts
Sponsored by

Key Data Points

Primary metrics and data points about Celgene.
Current Price: $108.79
Prev Close: $107.91
Open: $107.93
Bid: $108.80
Ask: $110.00
Day's Range: $107.50 - $110.13
52wk Range: $93.05 - $128.39
Volume: 4,728,157
Avg Vol 4,459,543
Market Cap: $85.47B
P/E (ttm): 45.34
EPS (ttm): $2.38
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Celgene.
CAPS Rating 5 out of 5
 
2166 Outperform
77 Underperform
CAPS All Stars
 
428 Outperform
11 Underperform

How do you think Celgene will perform against the market?



You pick for Celgene is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Mark J. Alles, CEO

94% Approve

Based on 9 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Celgene.

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers